Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
AB-3A4-ADC
- Development stage
- Preclinical
- Lead developer
- Alethia Biotherapeutics
- Modality
- Cytotoxic ADCs → Antibody-Drug Conjugates (ADCs) → Antibody Conjugates → Antibody-Based Therapeutics
- Administration
- Intravenous
01
Overview
AB-3A4-ADC is a preclinical-stage antibody-drug conjugate (ADC) developed by Alethia Biotherapeutics for the treatment of solid tumors, specifically ovarian cancer and triple-negative breast cancer (TNBC). The therapeutic candidate targets Kidney-associated antigen 1 (KAAG-1), a protein that is significantly overexpressed on the surface of various cancer cells while maintaining low expression in healthy tissues. By binding to KAAG-1, AB-3A4-ADC is internalized into the tumor cell, where it releases its cytotoxic payload to induce apoptosis. This targeted approach aims to increase the therapeutic index compared to conventional chemotherapy by minimizing off-target toxicity.
- Other names
- AB-3A4-ADCAB3A4-ADCAB 3A4-ADC
02
Targets
TUBB (Tubulin (alpha and beta subunits))KAAG1 (Kidney-associated antigen 1)
Beyond the preview
Go deeper on AB-3A4-ADC.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on AB-3A4-ADC.